- UAA Congress 2025

Back

Final Presentation Format

Non-Moderated Poster Abstract

Eposter Presentation

Eposter in PDF Format

https://storage.unitedwebnetwork.com/files/1237/16b5b602a4a15d8e1ce66f277ad70d7f.pdf

Accept format: PDF. The file size should not be more than 5MB

Eposter in Image Format

https://storage.unitedwebnetwork.com/files/1237/630c80317836abe0fab25a909e97b583.jpg

Accept format: PNG/JPG/WEBP. The file size should not be more than 2MB

Abstract

Abstract Title

EVALUATION OF CONSERVATIVE MANAGEMENT OUTCOMES FOR TUBEROUS SCLEROSIS COMPLEX-ASSOCIATED RENAL ANGIOMYOLIPOMAS TREATED WITH EVEROLIMUS

Presentation Type

Podium Abstract

Manuscript Type

Case Study

Abstract Category *

Oncology: Kidney (non-UTUC)

Author's Information

Number of Authors (including submitting/presenting author) *

No more than 10 authors can be listed (as per the Good Publication Practice (GPP) Guidelines).
Please ensure the authors are listed in the right order.

Co-author 1

Van Khoa Nguyen drnguyenvankhoa@gmail.com Binh Dan Hospital Urology Ho Chi Minh Vietnam *

Co-author 2

Anh Toan Do bsnguyenvankhoa@gmail.com Binh Dan Hospital Urology Ho Chi Minh Vietnam

Co-author 3

Co-author 4

Co-author 5

Co-author 6

Co-author 7

Co-author 8

Co-author 9

Co-author 10

Co-author 11

Co-author 12

Co-author 13

Co-author 14

Co-author 15

Co-author 16

Co-author 17

Co-author 18

Co-author 19

Co-author 20

Abstract Content

Introduction

Renal angiomyolipomas (AMLs) associated with tuberous sclerosis complex (TSC) often present bilaterally, posing a more challenging prognosis compared with sporadic lesions. These patients carry a high risk of nephrectomy and subsequently may develop chronic kidney disease (CKD). The ability to avoid surgical intervention while preventing complications represents a notable therapeutic advantage.

Materials and Methods

A case report of bilateral renal angiomyolipomas (AML) associated with tuberous sclerosis complex (TSC) in a patient with chronic kidney disease, treated with Everolimus and monitored over a three-month period.

Results

After three months of follow-up, the tumor size decreased by approximately 20%, renal function remained stable, and no significant adverse events were observed.

Conclusions

Everolimus demonstrates both safety and efficacy in treatment, with a comprehensive risk–benefit assessment indicating its promising potential as a therapeutic option for tuberous sclerosis complex–associated angiomyolipoma.

Keywords

Renal angiomyolipomas, TSC, Everolimus.

Figure 1

Figure 1 Caption

Figure 2

Figure 2 Caption

Figure 3

Figure 3 Caption

Figure 4

Figure 4 Caption

Figure 5

Figure 5 Caption

Presentation Order